Aurigene Pharmaceutical Services Limited (APSL) to use proprietary enzymatic technology for manufacturing
Fermenta Biotech Limited (FBL) blazoned that it has inked a definitive agreement with Aurigene Pharmaceutical Services Limited (APSL), a stepdown attachment of Dr Reddy’s Laboratories Limited (DRL). In this arrangement, FBL will simply certify its personal biocatalytic technology for conflation of molnupiravir and force its enzyme Candida Antarctica B Lipase (CAL B) to APSL, and APSL will simply land the enzyme from FBL.
Molnupiravir API manufactured by APSL will be employed by DRL for its expression. Also, APSL can also supply the API manufactured through this technology to other inventors of molnupiravir, a Covid-19 medicine that has lately entered exigency use blessing from the Food and Medicines Authority and Medicines Controller General of India.
This development follows FBL’s advertisement of filing patents for its new technology for synthesizing molnupiravir in April 2021. Latterly, the process has been further optimized at the laboratory scale, with demonstrations being successfully conducted at APSL’s R&D centre in Hyderabad. FBL’s biocatalytic technology possesses unique advantages similar as enzyme recyclability, optimum solvent recovery and bettered process effectiveness.
Prashant Nagre, managing director, FBL, reflected, “ Our technology, grounded on green chemistry, is one of the first of its kind in the world, enabling sustainable and scalable manufacture of molnupiravir. Also, through our moxie in enzymatic results, we also bring in cost effectiveness by using our in- house enzyme. We’re proud to play a part in our collaborative fight against Covid-19 by making this medicine more affordable.”
Suggested readings
About Author
